These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 18368132)

  • 1. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
    Najar HM; Dutz JP
    J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
    Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
    J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
    Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
    Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
    Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma.
    Kiyohara E; Tamai K; Katayama I; Kaneda Y
    Gene Ther; 2012 Jul; 19(7):734-41. PubMed ID: 21900962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
    Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
    J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
    Trefzer U; Sterry W
    Dermatology; 2005; 211(4):370-1. PubMed ID: 16286751
    [No Abstract]   [Full Text] [Related]  

  • 8. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
    Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
    Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
    Faião-Flores F; Quincoces Suarez JA; Fruet AC; Maria-Engler SS; Pardi PC; Maria DA
    PLoS One; 2015; 10(3):e0118702. PubMed ID: 25742310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
    Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
    Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
    van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
    Valero T; Steele S; Neumüller K; Bracher A; Niederleithner H; Pehamberger H; Petzelbauer P; Loewe R
    J Invest Dermatol; 2010 Apr; 130(4):1087-94. PubMed ID: 19940857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells.
    Kunikata N; Sano K; Honda M; Ishii K; Matsunaga J; Okuyama R; Takahashi K; Watanabe H; Tamura G; Tagami H; Terui T
    J Invest Dermatol; 2004 Aug; 123(2):395-402. PubMed ID: 15245441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma.
    Umeda T; Aoki K; Yokoyama A; Ohara H; Hayashi O; Tanaka K; Nishioka K
    J Dermatol; 1998 Sep; 25(9):569-72. PubMed ID: 9798342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
    Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
    Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.